BioSpace News Archive

Debiopharm announced an exclusive option and license agreement with SunRock Biopharma, a Galician company supported by the regional government, Xunta de Galicia, through Xesgalicia, devoted to the development of antibodies against highly invasive tumors with an urgent clinical need in oncology, for the advancement of the development of specifically targeted antibodies.

Medunik USA is pleased to announce that government coverage of Siklos® under State Medicaid programs is now available in 19 states: 5 states with preferred coverage: FL, TX, WI, & WY as well as on the Contract Drug List in California, and covered in another 14 states with prior authorizations*, in addition to the expanding commercial coverage for the benefit of Americans with sickle cell anemia.

Axsome Therapeutics, Inc. announced it is joining the global narcolepsy advocacy community, including more than 20 global patient advocacy organizations across six continents, to raise awareness of the impact that narcolepsy has on World Narcolepsy Day, Sept. 22, 2023.

Sensei Biotherapeutics, Inc. today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the U.S. commercial availability of NexoBrid® for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns.

Valneva SE, a specialty vaccine company, reported its consolidated financial results for the first half of the year, ended June 30, 2023.

Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies for CNS and eye diseases, announces the appointment of Lolita Petit, PhD as Chief Scientific Officer.

Aligos Therapeutics, Inc. announced it has received clearance of its Investigational New Drug application from the US Food and Drug Administration for ALG-055009, it’s thyroid hormone receptor beta agonist, intended for the treatment of nonalcoholic steatohepatitis.

Ocugen, Inc. today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB).

PolyPid Ltd. today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company’s manufacturing facility without any critical or major findings.